Immune therapy has not worked well in pancreatic cancer because of the cancer’s inherent immune resistance. Sylvester Comprehensive Cancer Center scientists have discovered a way to outsmart the deadly cancer’s ability to prevent immune checkpoint inhibitor therapy from killing pancreatic cancer cells.
Researchers at the NCI-designated Sylvester Comprehensive Cancer Center, working within several departments at the University of Miami Miller School of Medicine, have identified another critical component of the AML1-ETO multi-protein complex that could point the way to more effective therapies for acute myeloid leukemia (AML).
A study looking at PARP inhibition in diffuse large B cell lymphoma opens the door to a new way to treat this common type of cancer, according to study author Izidore S. Lossos, M.D., endowed director of the Lymphoma Program at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, and head of the Hematological Malignancies Site Disease Group.
Researchers have struggled with the challenge of getting oral medications past the treacherous environment of the gut intact and into the bloodstream where they can be most effective. But now Sylvester Comprehensive Cancer Center and University of Miami Miller School of Medicine researchers report success in accomplishing this breakthrough using nanotechnology.
Two recent studies by Sylvester Comprehensive Cancer Center researchers are the first to suggest that immunotherapy plays a key role in treating sarcomas, namely angiosarcoma and alveolar soft-part sarcoma. The findings could change the treatment paradigm for sarcoma types that have few if any treatment options.
A researcher at Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine has identified a potential target for halting the unchecked cell division in medulloblastoma, the most common pediatric brain tumor. However, laboratory studies indicate that inhibiting cellular division must be done carefully during a relatively narrow window of time to avoid damage to a child’s still-developing brain.
The Mary Brickell Trailblazer Award, named after one of Miami’s founders, is given by the Greater Miami Chamber of Commerce to those at the forefront of achieving something significant, a leader in their field. On August 7 that award was presented to Director Stephen D. Nimer, M.D., on behalf of Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.
Sylvester Comprehensive Cancer Center, part of the University of Miami Leonard M. Miller School of Medicine, has received the prestigious NCI designation from the National Cancer Institute.
The Florida Cancer Data System, located at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, recently received three important distinctions for the quality of its cancer registry data.
A group of researchers from Sylvester Comprehensive Cancer Center, the Department of Surgery and the Department of Medicine at the University of Miami Miller School of Medicine have found that probiotics can reduce morphine tolerance when used as an adjunct therapy in germ-free mice.